Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study

Original research
par
Lowenstein, Margaret et al

Date de publication

2025

Géographie

USA

Langue de la ressource

English

Texte disponible en version intégrale

Non

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

To assess real-world access to buprenorphine treatment in Philadelphia and measure adoption of policies and practices that facilitate buprenorphine access.

Constatations/points à retenir

107 programs were reached with audit calls (82 % response rate). 52 % were primary care offices and 48 % were specialty addiction providers. Median time-to-appointment was 3 business days (range 0–120), and 42 % of visits were offered with a single call. Only 42 % of programs could confirm the possibility of a buprenorphine prescription at an initial visit. 48 % of programs could not provide information about requirements for counseling or behavioral health, and few could provide information about policies for patients with ongoing substance use. Specialty models were more likely than primary care programs to provide information about medication availability at the first visit but also were more likely to require counseling and abstinence.

La conception ou méthodologie de recherche

We used an audit (“secret shopper”) design to survey all programs providing longitudinal, outpatient buprenorphine in Philadelphia from 9/2022–1/2023 (n = 130). 

Mots clés

Barriers and enablers
Policy/Regulatory
Substitution/OAT
Treatment/recovery